Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2021-03-05 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has signed Rohit Sharma as the brand ambassador for their Candid Powder product. It is addressed to stock exchanges and requests the announcement to be taken on record. The content focuses on marketing and brand endorsement rather than financial results, management changes, or regulatory filings. There is no financial data, no mention of annual or quarterly reports, no voting results, no legal proceedings, or capital changes. The document is a corporate announcement related to marketing and brand promotion. Therefore, it does not fit into financial report categories but is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement made to stock exchanges that does not fit other specific categories.
2021-03-05 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals received the 'India Pharma Innovation of the Year' Award from the Government of India. It is addressed to stock exchanges and includes a media release for immediate distribution. There are no financial statements, regulatory filings, or detailed reports included. The content is an announcement of an award, not a financial report, management change, or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a general corporate announcement related to recognition and awards. Given the nature and length (4669 characters), it is not a report publication announcement or a regulatory filing. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-02-25 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the marketing approval and upcoming commercialization of Glenmark's Ryaltris nasal spray in Russia. It is addressed to stock exchanges and includes a media release with product details, market information, and company background. There are no financial statements, regulatory filings, or detailed financial data. The content is promotional and informational about a product launch rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is Regulatory Filings (RNS) as a general announcement to the stock exchanges that does not fit other specific categories.
2021-02-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, SUTIB (Sunitinib), by Glenmark Pharmaceuticals. It includes details about the product, pricing, and its medical benefits. The document is addressed to stock exchanges and is intended as a media release for immediate distribution. There is no financial data, regulatory filing, or report content such as annual or quarterly financial results, audit information, or management discussion. It is a corporate announcement related to product launch and marketing, not fitting into financial or regulatory report categories. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories. The document length is 5312 characters, which is sufficient for a full press release rather than a brief announcement or report publication notice.
2021-02-16 English
Outcome of Board Meeting
Regulatory Filings
2021-02-12 English
Financial Result Updates
Regulatory Filings
2021-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.